



Aligning Patient and Clinician Goals to Improve the Care of Ovarian Cancer

Clinical Brief #3 – Emerging Role of Initial and Maintenance Therapy With PARPi + IO Combinations

References

Tweet 2 References:

Harter P, Trillsch F, Okamoto A, et al. Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCaM): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial. *J Clin Oncol*. 2023;41(suppl 17). doi:10.1200/JCO.2023.41.17_suppl.LBA5506

Additional References:

Albrecht TL, Eggly SS, Gleason ME, et al. Influence of clinical communication on patients' decision making on participation in clinical trials. *J Clin Oncol*. 2008;26(16):2666-73. doi:10.1200/JCO.2007.14.8114

ClinicalTrials.gov. A Comparison of platinum-based therapy with TSR-042 and niraparib versus standard of care (SOC) platinum-based therapy as first-line treatment of stage III or IV nonmucinous epithelial ovarian cancer (FIRST). NCT03602859. Updated August 2, 2023. Accessed August 9, 2023. <https://clinicaltrials.gov/study/NCT03602859>

ClinicalTrials.gov. Study of chemotherapy with pembrolizumab (MK-3475) followed by maintenance with olaparib (MK-7339) for the first-line treatment of women with brca non-mutated advanced epithelial ovarian cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036). NCT03740165. Updated February 10, 2023. Accessed August 9, 2023. <https://clinicaltrials.gov/study/NCT03740165>

Coleman RL, Fujiwara K, Sehouli J, et al. ENGOT-ov43/keylynk-001: A phase III, placebo- and active-controlled trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of advanced BRCA-nonmutated epithelial ovarian cancer. *Gynecol Oncol*. 2020;159:89-90. doi:10.1016/j.ygyno.2020.05.070

Epstein RM, Duberstein PR, Fenton JJ, et al. Effect of a patient-centered communication intervention on oncologist-patient communication, quality of life, and health care utilization in advanced cancer. *JAMA Oncology*. 2017;3(1):92-100. doi:10.1001/jamaoncol.2016.4373

Foundation for Women's Cancer. Clinical Trial Basics. Updated 2023. Accessed August 9, 2023. <https://foundationforwomenscancer.org/clinical-trials/clinical-trial-basics/>

Hardy-Bessard A-C, Moore KN, Mirza MR, et al. ENGOT-OV44/FIRST study: a randomized, double-blind, adaptive, phase III study of standard of care (SOC) platinum-based therapy ± dostarlimab followed by niraparib ± dostarlimab maintenance as first-line (1L) treatment of stage 3 or 4 ovarian cancer (OC). *J Clin Oncol*. 2020;38(suppl 15). doi:10.1200/JCO.2020.38.15_suppl.TPS6101



Kim Y-N, Park B, Kim J-W, et al. Triplet maintenance therapy of olaparib, pembrolizumab and bevacizumab in women with BRCA wild-type, platinum-sensitive recurrent ovarian cancer: the multicenter, single-arm phase II study OPEB-01/APGOT-OV4. *Nat Commun.* 2023;14(1):5476.

Kim YN, Park B, Joung J-G, et al. Triplet maintenance (olaparib, pembrolizumab, and bevacizumab) in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer: A multi-center, single-arm phase II study (OPEB-01). *J Clin Oncol.* 2023;41(suppl 16):5584. doi:10.1200/JCO.2023.41.16_suppl.5584

Glossary

1L, first line
2L, second line
a, advanced
adj, adjuvant
AE, adverse event
BEV, bevacizumab
BRCA, breast cancer gene
Chemo, chemotherapy
CI, confidence interval
CR, complete response
Dosta, dostarlimab
DOX, doxorubicin
Durva, durvalumab
dx, diagnosis
FR, folate receptor
HGEOC, high-grade epithelial ovarian cancer
HR, hazard ratio
HRd, homologous recombination deficient
HRp, homologous recombination proficient
HRQoL, health-related quality of life
i, inhibitor
IO, immunotherapy
ND, newly diagnosed
Neoadj, neoadjuvant
NR, not reached
OC, ovarian cancer
ORR, objective response rate
OS, overall survival
PARPi, Poly (ADP-ribose) polymerase inhibitor
Pembro, pembrolizumab
PFS, progression-free survival
PR, partial response
t, tumor
TMB, tumor mutational burden



w/, with
w/o, without
wt, wild type
yo, year old